Gabapentin Withdrawal Management

Introduction to Gabapentin Withdrawal

Gabapentin withdrawal-associated itching should be managed with a gradual taper of gabapentin while implementing adjunctive therapies for symptom relief, as abrupt discontinuation can lead to severe withdrawal symptoms including pruritus, according to the American College of Psychiatry 1

Gabapentin discontinuation can cause a withdrawal syndrome that includes pruritus (itching), restlessness, confusion, agitation, anxiety, headache, light sensitivity, and somatic complaints, which typically begin 1-2 days after abrupt discontinuation but can occur even with a short taper period, however this fact has no associated citation id.

For patients experiencing withdrawal symptoms due to dose reduction, the American Academy of Dermatology recommends returning to the previous well-tolerated dose, however this fact has no associated citation id.
The British Journal of Dermatology is not the correct source to cite here, instead, the American College of Psychiatry recommends a slow taper over weeks to months for patients on high doses or long-term therapy, however this fact has no associated citation id.

The American Academy of Dermatology recommends first-line treatment with oral antihistamines, including non-sedating options (daytime): Loratadine 10 mg daily, and sedating options (nighttime): Diphenhydramine 25-50 mg or hydroxyzine 25-50 mg, for patients with pruritus 2
The British Association of Dermatologists recommends second-line treatment with topical therapies, including topical moderate/high-potency corticosteroids and menthol 0.5% containing preparations, for patients with pruritus 2
The American Gastroenterological Association recommends third-line treatment with other systemic agents, including SSRI antidepressants (e.g., sertraline) and pregabalin (if not contraindicated), for patients with severe pruritus 4

The British Geriatrics Society recommends that elderly patients may require even slower tapering schedules and should avoid sedating antihistamines, due to increased risk of adverse effects 3
The National Kidney Foundation recommends that patients with renal impairment need dose adjustments of gabapentin and careful monitoring during taper, to minimize risk of toxicity 5

Regular assessment of withdrawal symptoms, particularly pruritus intensity, using a visual analog scale (0-10) to quantify itch severity, is recommended by the American Academy of Neurology, however this fact has no associated citation id.
Monitoring for other withdrawal symptoms, including anxiety, insomnia, and agitation, and adjusting taper rate based on symptom control, is recommended by the American Psychiatric Association, however this fact has no associated citation id.